Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9HC36
UPID:
MRM3_HUMAN
Alternative names:
16S rRNA (guanosine(1370)-2'-O)-methyltransferase; 16S rRNA [Gm1370] 2'-O-methyltransferase; RNA methyltransferase-like protein 1
Alternative UPACC:
Q9HC36; Q53GN1; Q86VC3; Q96F76; Q9NVQ5
Background:
rRNA methyltransferase 3, mitochondrial, also known as 16S rRNA (guanosine(1370)-2'-O)-methyltransferase, plays a crucial role in mitochondrial function by catalyzing the formation of 2'-O-methylguanosine at position 1370 in the 16S mitochondrial large subunit ribosomal RNA. This modification is vital for the peptidyl transferase domain's function in protein synthesis.
Therapeutic significance:
Understanding the role of rRNA methyltransferase 3, mitochondrial could open doors to potential therapeutic strategies.